Bharat Parenterals Proposes ₹139 Crore Preferential Issue and Enhanced Investment Limits
Bharat Parenterals Ltd · Extra Ordinary General Meeting · 01 Oct 2026, 11:09 pm
Bharat Parenterals Proposes ₹139 Crore Preferential Issue and Enhanced Investment Limits Bharat Parenterals scheduled an EGM for 23rd Oct'26 to approve raising up to ₹139.00 crore via a preferential issue of 9,12,759 equity shares at ₹1,522.85 per share to non-promoter institutional and individual investors, including WhiteOak Capital entities. Proceeds will primarily fund investments in subsidiaries (up to ₹135.00 crore) and general corporate purposes. The issue will dilute promoter holding from 67.20% to 59.35%. Additionally, the company seeks shareholder approval to enhance its investment, loan, guarantee, and security limits under Section 186 up to ₹140.00 crore.
Original exchange filing (PDF)
More announcements from Bharat Parenterals Ltd
- Intimation for receipt of Establishment Inspection Report from US FDA by Innoxel Lifesciences Pvt Ltd., a subsidiary company of Bharat Parenterals Limited. · 05 Nov 2026
- Transcript of Earnings Conference Call of Q2FY27. · 02 Nov 2026
- Audio Recording of Q2FY27 Earnings Conference Call. · 30 Oct 2026
- Investor Presentation for the Quarter and Half Year ended on September 30, 2026. · 29 Oct 2026
- Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026. · 29 Oct 2026
- Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026 · 29 Oct 2026
- Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026. · 25 Oct 2026
- Revised Voting Result · 25 Oct 2026
